Physician profile
Michael Devera
NPI 1407829658
$10,907.59
in general payments reported to CMS, 2019-2025
18 companies · $9,621 in 2025
The $9,621 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $18.84 · 2022: $320 · 2023: $140 · 2024: $654 · 2025: $9,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,250 · Travel and Lodging: $2,416 · Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,250.00 |
| Travel and Lodging | $2,416.33 |
| Food and Beverage | $1,748.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,728.30 | 2025 | |
| Abbvie INC. | $352.20 | 2022-2025 | Mavyret |
| Xvivo Perfusion INC. | $351.83 | 2024-2025 | Xvivo Perfusion System (Xps) |
| Ethicon US, LLC | $321.65 | 2022-2025 | Vistaseal, Evarrest, Ethicon |
| Veloxis Pharmaceuticals, INC. | $172.31 | 2019-2020 | |
| Integra Lifesciences Corporation | $171.33 | 2022-2025 | Codman Certas, Cusa Clarity, Codman Hakim |
| Organox Ltd | $154.26 | 2025 | |
| Paragonix Technologies, INC. | $153.90 | 2024 | Pancreaspak, Sherpapak, Liverguard |
| Boston Scientific Corporation | $147.39 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Mallinckrodt Hospital Products INC. | $69.06 | 2024-2025 | Terlivaz |
| Olympus America INC. | $58.11 | 2022-2025 | Olympus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.70 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $48.64 | 2023-2024 | Livtencity |
| Bridge To Life Ltd | $41.64 | 2023 | |
| Hemosonics LLC | $35.58 | 2023 | Quantra Qplus System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $21.59 | 2024 | Livmarli |
| E.R. Squibb & Sons, L.L.C. | $15.19 | 2024 | Nulojix |
| Stryker Corporation | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Devera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.